Overview
New York-based biotech startup Proxima has secured $80 million in seed funding to revolutionize how medicines interact with cells. The funding round was led by DCVC, with participation from notable investors including NVIDIA’s venture capital arm, nVentures. Proxima aims to address the limitations of traditional drug discovery by developing proximity-based medicines that reshape protein networks, potentially treating diseases that have resisted conventional approaches.
Products
Loading...
Recent Deals
Investors: DCVC, nVentures
New York-based biotech startup Proxima has secured $80 million in seed funding to revolutionize how medicines interact with cells. The funding round was led by DCVC, with participation from notable investors including NVIDIA’s venture capital arm, nVentures. Proxima aims to address the limitations of traditional drug discovery by developing proximity-based medicines that reshape protein networks, potentially treating diseases that have resisted conventional approaches.